IP Library Granted Patent US 10,208,044
Granted Patent B2
US 10,208,044 · App. 14/890,358 · Granted Feb 19, 2019

ACC inhibitors and uses thereof

Inventors: Jeremy Robert Greenwood (Brooklyn, NY); Geraldine C. Harriman (Charlestown, RI); George Borg (Somerville, MA); Craig E. Masse (Cambridge, MA)
Assignee: GILEAD APOLLO, LLC
C07D487/04A01N43/76A01N43/90C07D403/04C07D405/12C07D405/14C07D413/04C07D413/14C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,208,044
App. No.
14/890,358
Granted
Feb 19, 2019
Kind
B2
Abstract

The present invention provides for compounds of formula I as acetyl-CoA carboxylase (ACC) inhibitors. The ACC inhibitors are useful for the prevention or treatment of metabolic syndrome, including obesity, dyslipidemia and hyperlipidemia in humans. The inhibitor compounds are also capable of inhibiting the ACC enzyme found in plants, parasites and bacteria.

Claims (14)

1. A compound of formula:

or a pharmaceutically acceptable salt thereof.

2. A composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

3. A method of inhibiting ACC in a biological sample, comprising contacting the biological sample with an effective amount of the compound according to claim 1 .

4. A method of inhibiting ACC in a plant, comprising contacting the plant with an effective amount of the compound according to claim 1 .

5. A method of treating non-alcoholic steatohepatitis (NASH) in a patient in need thereof, comprising administering to said patient an effective amount of the composition according to claim 2 .

6. A method of inhibiting Acetyl-CoA carboxylase (ACC) in a patient in need thereof, comprising administering to said patient an effective amount of the composition according to claim 2 .

7. A method for treating a metabolic disorder susceptible to treatment with an ACC inhibitor in a patient in need thereof, comprising administering to said patient an effective amount of the composition according to claim 2 .

8. The method according to claim 7 , wherein the metabolic disorder is obesity.

9. The method according to claim 8 , wherein the obesity is a symptom of Prader-Willi syndrome, Bardet-Biedl syndrome, Cohen syndrome or Macrosomia, Obesity, Macrocephaly, and Ocular (“MOMO”) syndrome.

10. The method according to claim 8 , wherein the obesity is a side effect of the administration of another medication selected from insulin, a sulfonylurea, a thiazolidinedione, an antipsychotic, an antidepressant, a steroid, an anticonvulsant, pizotifen, and a hormonal contraceptive.

11. The method according to claim 7 , wherein the metabolic disorder is dyslipidemia or hyperlipidemia.

12. A method of treating a cancer or other proliferative disorder susceptible to treatment with an ACC inhibitor in a patient in need thereof, comprising administering to said patient an effective amount of the composition according to claim 2 .

13. A method of treating a fungal, parasitic, or bacterial infection susceptible to treatment with an ACC inhibitor in a patient in need thereof, comprising administering to said patient an effective amount of the composition according to claim 2 .

Assignments (3)
CHANGE OF NAME Recorded Oct 3, 2016
From: GILEAD APOLLO, INC.
To: GILEAD APOLLO, LLC
Reel/Frame 040209/0033 →
MERGER AND CHANGE OF NAME Recorded Jul 27, 2016
From: NIMBUS APOLLO, INC.; GILEAD APOLLO, INC.
To: GILEAD APOLLO, INC.
Reel/Frame 039490/0648 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2015
From: GREENWOOD, JEREMY ROBERT; HARRIMAN, GERALDINE C.; BORG, GEORGE; MASSE, CRAIG E.
To: NIMBUS APOLLO, INC.
Reel/Frame 037075/0679 →
Continuity (2)
Provisional Application 61821831 · May 10, 2013
Related Publication 20160185783A1 · Jun 30, 2016
Cited By (1)
US 12,428,432